Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks with Bloomberg's Dani Burger.

Ethan Allen CEO Farooq Kathwari Talks Tariffs, Cautious Consumers
06:32

Yale Budget Lab Executive Director Martha Gimbel Talks Tariffs
05:24

Apollo's Jim Zelter Talks Iran War, Private Credit Concerns
10:35